Nanoparticle vaccines against respiratory viruses

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 1, Issue 4, 2009, Pages 405-414

  Adair, Brian M ^a  

^a AGRI FOOD AND BIOSCIENCES INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE RESPONSE; INFLUENZA VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RESPIRATORY TRACT; UPPER RESPIRATORY TRACT; VACCINE EFFICACIES; VIRAL PROTEINS; VIRUS INFECTION;

ANTIBODIES; IMMUNE SYSTEM; NANOPARTICLES; VACCINES;

VIRUSES;

NANOPARTICLE; RECOMBINANT VACCINE; VIRUS ANTIGEN; VIRUS VACCINE;

HUMAN; IMMUNOLOGY; ORTHOMYXOVIRUS; PARAINFLUENZA VIRUS 3; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; VIROLOGY;

ANTIGENS, VIRAL; HUMANS; NANOPARTICLES; ORTHOMYXOVIRIDAE; PARAINFLUENZA VIRUS 3, HUMAN; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 77949326906     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.45     Document Type: Article

References (68)

1. Brandenburg AH, Neijens HJ, Osterhaus AD. Patho-genesis of RSV lower respiratory tract infection:implications for vaccine development. Vaccine2001,19:2769-2782
2. Falsey AR, Walsh EE. Respiratory syncytial virus infec-tion in adults.Clin Microbiol Rev2000, 13:371-384.
3. Valarcher J-F, Taylor G. Bovine respiratory syncytial virus infection.Vet Res2007, 38:153-180
4. Kraal, G. Nasal-associated lymphoid tissue. In Mestecky J, Lamm ME, McGhee JR, Bienenstock J, Mayer L,et al. eds. Mucosal Immunology. London, New York: Elsevier/Academic Press; 2005, 415-422.
5. Bienenstock J, Befus D. Gut-and bronchus-associated lymphoid tissue. Am J Anat1984, 170:437-445.
6. Hall WJ, Hall CB, Speers DM. Respiratory syncy-tial virus infection in adults: clinical, virologic and serial pulmonary function studies.Ann Int Med1978,88:203-205.
7. Zhang L, Peeples ME, Boucher RC, Collins PL, Pick-les RJ. Respiratory syncytial virus infecion of human airway epithelial cells is polarized, specific to ciliated cells and without obvious cytopathology.JVirol2002, 76:5654-5666.
8. Zhang L, BukreyevA, ThompsonCI,Watson B, Peeples ME, et al. Infection of ciliated cells by human parain-fluenza virus type 3 in an in vitro model of human airway epithelium.JVirol2005, 79:1113-1124.
9. Schmitt AP, Lamb RA. Influenza virus assembly and budding at the viral budozone.Adv Vir Res2005,64:383-416.
10. Viuff B, Tjornehoj K, Larsen LE, Rontved CM, Utten-thal A, et al. Replication and clearance of respiratory syncytial virus: apotosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus.Am J Pathol2002, 161:2195-2207.
11. Kuper CF, Koornestrat PJ, Hameleers DMH, Biewenga J, Spit BJ, et al. The role of naspharyngeal lymphoid tissue.Immunol Today1992, 13:219-224.
12. Tamura S-I, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jap J Inf Dis2004, 57:236-247.
13. Zuercher AW. Upper respiratory tract immunity.Vir Immunol2003, 16:279-289.
14. Heritage PL, Brook MA, Underdown BJ, McDermott MR. Intranasal immunization with polymer-grafted microparticles activates the nasal associated lymphoid tissue and draining lymph nodes. Immunology 1998, 93:249-256.
15. PerryM,WhyteA. Immunology of the tonsils.Immunol Tod1998, 19:414-421.
16. Zuercher AW, Coffin SE, Thurnheer MC, Fundova P, Cebra JJ. Nasal-associatedlymphoid tissue is amucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol2002, 168:1796-1803.
17. Crowe EJ. Influence of maternal antibodies on neona-tal immunization against respiratory viruses.Clin Infect Dis2001, 33:1720-1727.
18. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines.Trends Immunol2006, 27:573-579.
19. Bennewitz NL, Babensee JE. The effect of the phys-ical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. Biomat2005, 26:2991-2999.
20. Yoshida M, Babensee JE. Poly (lactic-co-glycolic acid) enhances maturation of human monocyte-derived den-dritic cells.JBiomed Mater Res2004, 71A:45-54.
21. Des Rieux A, Fievez V, Garinot M, Schneider Y-J, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.J Cont Rel2006, 116:1-27.
22. Cui Z, Hsu C-H,Mumper RJ. Physical characterization and macrophage uptake of mannan-coated nanoparti-cles.Drug Dev Ind Pharm2003, 29:689-700.
23. Kwon YJ, James N, Shastri N, Frechet JM.In vivo targeting of dendritic cells for activation of cellu-lar immunity using vaccine carriers based on pH-responsive microparticles. Proc Nat Acad Sci (USA) 2005, 102:18264-18268.
24. Janes KA, Calvo P, AlonsoMJ. Polysaccharide colloidal particles as delivery systems for macromolecules.Adv Drug Del Rev2001, 47:83-97.
25. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vac-cines.AdvDrugDelRev2001, 51:81-96.
26. Gan Q, Wang T, Cochrane C, McCarron P. Modula-tion of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery.Coll Surf B2005, 44:65-73.
27. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, et al. The virosome concept for influenza vaccines.Vaccine2005, 23S1 S1/26-S1/38.
28. Cusi MG, Zurbriggen R, Correale P, Valassina M, Terrosi C, et al. Influenza virosomes are in efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.Vaccine 2002, 20:3436-3442.
29. Morein B, Lovgren-Bengtsson K. Functional aspects of iscoms.Imm Cell Biol1998, 76:295-299.
30. Mumford JA, Jesset D, Dunleavy U, Wood J, Hannant D, et al. Antigenicity and immunogenicity of exper-imental equine influenza ISCOM vaccines. Vaccine 1994, 12:857-863.
31. Sundqvist B, Lovgren K, Morein B. Influenza virus iscoms: antibody response in animals. Vaccine1988,6:49-52.
32. Rimmelzwaan GF, Baars M, van Beek R, van Ameron-gen G, Lovgren-Bengtsson K, et al. Induction of pro-tective immunity against influenza virus in a macaque model: comparison of conventional and iscomvaccines. JGen Virol1997, 78:757-765.
33. Hu K-F, Elvander M, Merza M, Akerblom L, Bran-denburg A, et al. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducintg high local and systemic antibody responses. Clin Exp Immunol1998, 113:235-243.
34. Hagglund S, Hu K-F, Larsen LE, Hakhverdyan M, Valarcher J-F, et al. Bovine respiratory syncytial virus ISCOM's-protection in the presence of maternal anti-bodies.Vaccine2004, 23:646-655.
35. Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface modified microparticles in dendritic cells and macrophages. Pharm Res2003, 20:221-228.
36. Xiang S, Scholzen A,MinigoG, DavidC, Apostolopou-los V, et al. Pathogen recognition and developments of particulate vaccines: does size matter?.Methods2006, 40:1-9.
37. Lanzavecchia A. Mechanisms of antigen uptake for presentation.Cur Op Immunol1996, 8:348-354.
38. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunol-ogy1994, 81:661-667.
39. Men Y, Tamber H, Audran R, Gander B, Corradin G. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL pep-tide entrapped in biodegradable polymer microspheres. Vaccine1997, 15:1405-1412.
40. Moore A, McGuirk P, Adams S, Jones WC, McGee JP, et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+cytotoxic T lymphocytes and CD4+Th1 cells.Vaccine1995, 13:1741-1749.
41. Nixon DF, Hioe C, Chen P, Bian Z, Kuebler P, et al. Synthetic peptides entrapped inmicroparticles can elicit cytotoxic T cell activity.Vaccine1996, 14:1523-1530.
42. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune response after sub-cutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine2002, 21:67-77.
43. Mottram P, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, et al. Type 1 and 2 immunity following vac-cination is influenced by nanoparticle size: Formulation of a model vaccine for respiratory syncytial virus.Mol Pharm2006, 4:73-84.
44. Tamura S-I, Kurata T. Intranasal immunization with influenza vaccine. In Kiyono H, Ogra PL, McGhee JR. eds. Mucosal Vaccines. San Diego: Academic Press; 1996, 425-436.
45. Wiley JA, Hogan RJ, Woodland DL, Harmsen AG. Antigen-specific CD8+T cells persist in the upper respiratory tract following influenza virus infection. J Immunol2001, 167:3293-3299
46. McMichael A Cytotoxic T lymphocytes specific for influenza virus. Cur Top Microbiol Immunol1994,189:75-91.
47. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immu-nized intranasally with adjuvant-combined vaccines.J Immunol2002, 168:2930-2938.
48. Ito R, Yoshikawa T, Ozaki Y, Hasegawa H, Suzuki Y, et al. Roles of anti-hemagglutinin IgA and IgG antibod-ies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza virus pneumonia. Vaccine2003, 21:2362-2371.
49. Lemoine D, Preat V. Polymeric nanoparticles as deliv-ery system for influenza virus glycoproteins.J Cont Rel 1997, 54:15-27.
50. Moldoveanu Z, Novak M, Huang WQ, Gilley RM, Staas JK, et al. Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 1993,167:84-90.
51. Hilbert AK, Fritzsche U, Kissel T. Biodegradable microspheres containinginfluenza A vaccine: immune response in mice.Vaccine1999, 17:1065-1073.
52. Sun H, Pollock KG, Brewer JM. Analysis of the role of vaccine adjuvants in modulating dendritic cell activa-tion and antigen presentation in vitro. Vaccine2003,21:849-855.
53. AmidiM, Romeijn SG, Verhoef JC, Junginger HE, Bun-gener L, et al. N-Trimethyl chitosan (TMC) nanoparti-cles loadedwith influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model.Vaccine2007, 25:144-153.
54. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinatedwith an inac-tivatedRS virus vaccine.Am J Epid1969, 89:405-421.
55. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.Am J Epid1969, 89:442-434.
56. Kimman TG, Sol J, Westenbrink F, Straver PJ. A severe outbreak of respiratory disease associated with BRSV probably enhanced by vaccination with a modified live virus.Vet Quart1989, 11:250-253.
57. Gershwin LJ, Woolums AR, Gunther RA, Anderson ML, LaRochelle DRBGA, et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophys-iology.Vaccine1998, 16:1225-1236.
58. Schreiber P, Matheise JP, Dessy F, Heimann M, Letes-son JJ, et al. High mortality rate associated with bovine respiratory syncytial virus infection in Belgian White Blue calves vaccinated with an inactivated BRSV vac-cine.JVetMed B2000, 47:535.
59. Kimman TG, Zimmer GM, Westenbrink F, Mars J, Van Leeuwen E. Epidemiological study of bovine res-piratory syncytial virus infection in calves: Influence of maternal antibodies on the outcome of disease.Vet Rec 1988, 124:104-109.
60. BastienN, TrudelM, SimardC. Complete protection of mice from respirtory syncytial virus infection following mucosal delivery of synthetic peptide vaccines.Vaccine 1999, 17:832-836.
61. Richardson CR, Scheid A, Choppin PW. Specific inhi-bition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of F1 or the HA2 viral polypep-tides.Virology1980, 105:205-222.
62. Zhang W, Yang J, Kong X, Mohapatra S, San Juan-Vergara H, et al. Inhibition of respiratory syncytial virus infectionwith intranasal siRNAnanoparticles tar-geting the viralNS1 gene.NatureMed2004, 11:56-62.
63. Kong X, Zhang W, Lockey RF, Auais A, Piedimonte G, et al. Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene.Gen Vacc Ther2007, 5:1-8.
64. Durban JE, Durban RK. Respiratory syncytial virus induced immunoprotection and immunopathology. Viral Immunol2004, 17:370-380.
65. Ray R, Novak M, Duncan JD, Matsuoka Y, Compans RW. Microencapsulated Human Parainfluenza virus induces a protective immune response. J Infect Dis 1993, 167:752-755.
66. ShephardMJ, ToddD, Adair BM, LiWan PoA,Mackie DP, et al. Immunogenicity of bovine parainfluenza type 3 virus proteins encapsulated in nanoparticle vaccines, following intranasal administration to mice. Res Vet Sci2003, 74:187-190.
67. Kavanagh OV, Earley B, Murray M, Foster JC, Adair BM. Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(dl-lactide-co-glycolide) microspheres. Vaccine 2003, 21:4472-4480.
68. Rebelatto MC, Guimond P, Bowersock TL, Hogenesch H. Induction of systemic andmucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol2001, 83:93-105